Vinsight is a biotechnology startup founded in Istanbul in 2025 that develops clinically approved biosensor technologies.

Our goal is to make health monitoring accessible to everyone, removing the need for days-long laboratory processes and using portable, user-friendly devices that provide results in 2 minutes.

  • Clinically Approved: All tests have been successfully completed and approved by Dokuz Eylül University.

  • Technology: Our Molecularly Imprinted Polymer (MIP) + Quantum Dot doped sensors offer high accuracy and stability.

  • Product Range: Vinsense Lab for clinical researchers, Vinsense One for individuals.

  • Security: Our devices are non-invasive, KVKK compliant, and for informational purposes only.

Our vision is to be a global leader in non-invasive biosensors; our mission is to provide individuals and researchers with fast, reliable and easy access to their health data.

  • Corporate Promotion

    Vinsight is a biotechnology startup founded in Istanbul in 2025. Our mission is to move human health monitoring from days-long laboratory tests to portable biosensors that deliver reliable results in 2 minutes.

  • Clinical Reliability

    • The sensors and devices we developed have been clinically approved by Dokuz Eylül University.
    • All clinical tests and validation studies have been successfully completed, and the accuracy and reliability of our devices have been scientifically proven.
    • In this way, the data presented to both researchers and individuals are under clinical assurance.

  • Our technology

    • Molecularly Imprinted Polymer (MIP)-based electrodes
    • High conductivity, low signal-to-noise ratio and long-term stability with quantum dot doping
    • Standard deviation of less than 1% in measurements, i.e. over 99% repeatability
    • 0.01 µM detection limit for serotonin measurements – well below physiological levels in literature, high sensitivity

  • Our products

    • Vinsense Lab: An independent device for clinical research centers and R&D. Measures cortisol, serotonin, and melatonin in 2 minutes.
    • Vinsense One: A mobile-compatible device for individual users. It instantly transfers measurement results to the phone and offers AI-powered recommendations.

  • Competitive Advantage

    • While tests on the market require 7–21 days for results, Vinsight devices provide instant measurements in 2 minutes.
    • Unlike competing electrochemical devices, it is not connected to a computer and does not require an expert.
    • It stands out in accuracy and reliability with its clinically approved, quantum dot supported sensor technology.

  • Growth Strategy

    • In the short term: Market penetration in Turkey and Europe
    • In the medium term: Expansion of the product range with additional biomarkers (dopamine, norepinephrine)
    • In the long term: To become the leading brand in the global non-invasive biosensor market